- Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine/nab-paclitaxel SoC - - VCN-01 was well-tolerated, with transient and reversible adverse events (AEs), meeting primary safety endpoint - - Greater differences between the treatment arms were observed in patients receiving 2 doses of VCN-01 - -

The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds enrollment completed for the overall trial Results on track for interim data in Q2 2025 and topline data in Q3 2025 Management releases “What This Means” segment discussing the interim biomarker data; Access Here May 08, 2025 (GL

May 08, 2025 -- OrganOx Ltd., a leading organ medical technology company, completed a second closing of its private placement with investments from Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare LLC. Together with the first closing of its private placement on February 24, 2025, OrganOx raised $160 million in primary and secondary equity financing to accelerate growth opportunities for its metra® platform technology in the large and high growth organ technology global market

May 07, 2025 -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, one of the most prominent global conferences in liver disease. The poster suppo

May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam. Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on no

May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA).[1] Geographic atrophy (GA) is an eye disease that can lead to irreversible vision loss.[2] It affects more than five million people worldwide, of which more than 40% are considered blind, ,[3],[4] severely impacting their independence, mental health and quality of

May 07, 2025 -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new results with LX-101 in Thyroid Eye Disease (TED) have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, on May 7th in Salt Lake City, Utah. These new data highlight LX-101’s ability to effectively target multiple key processes in the underlying i

Provides ReciBioPharm’s customers with access to NewBiologix’s Xcell-Eng-HEK293 cell lines for advanced therapies Complements and further expands ReciBioPharm’s AAV offering Achieves industry-leading results across multiple AAV programs May 08, 2025 -- NewBiologix, a technology innovation company enabling efficient, cost-effective, and scalable production of viral vectors for cell and gene therapy (C>), today announced it has granted a non-exclusive technology license to ReciBioPharm – Reci

May 07, 2025 -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present new preclinical results on its GalOmic small‑interfering RNA (siRNA) candidate ETX‑312 for the treatment of metabolic dysfunction‑associated steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Congress, 7th-10th May 2025. In the leading Gubra‑Amylin NASH diet‑induced obese (GAN‑DIO) mouse

Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 2025 May 07, 2025 -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune dise